OpenLB
Open Library of Bioscience
Advanced Search

Journal

Publication Year

1 year 3 years 5 years 10 years
2021 - 2032
202120222023
202420252026
202720282029
203020312032
2021 - 2032
202120222023
202420252026
202720282029
203020312032

Publication Type

Associated Data

Found 65,803 results

Filters: Immunogenicity

Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation.
Daphne Guinn, Rajanikanth Madabushi, Yow-Ming Wang, Eric Brodsky, Issam Zineh, Kimberly Maxfield
Ther Innov Regul Sci. 11, 2020.54(6):1363-1371 Print-Electronic
Source:PubMed
PMID: 33258100 doi:10.1007/s43441-020-00161-z
European Immunogenicity Platform 11th Open Scientific Symposium on immunogenicity of biopharmaceuticals.
Sophie Tourdot, Carolina B Quaglia, Paul Chamberlain, Anne S De Groot, Nikki Dellas, Eric Guillemare, Arno Kromminga, Gregor P Lotz, Federico Mingozzi, Luca Piccoli, Samuel Pine, Susan Richards, G��nter Waxenecker, Daniel Kramer
Bioanalysis. Aug, 2020.12(15):1043-1048 Print-Electronic
Source:PubMed
PMID: 32803994 doi:10.4155/bio-2020-0150
A new era for proteomics.
John F Kellie, Timothy W Sikorski, Bo An, Zhuo Chen, Ahmed H Moghieb, Maria G Busz, Matthew E Szapacs, Thomas E Angel
Bioanalysis. Oct, 2019.11(19):1731-1735 Print-Electronic
Source:PubMed
PMID: 31617394 doi:10.4155/bio-2019-0191
An overview of scientific and regulatory issues for the immunogenicity of biological products.
P Chamberlain, A R Mire-Sluis
Dev Biol (Basel). 2003.112:3-11 Print
Source:PubMed
PMID: 12762499 doi:
Estimating the immunogenicity of blood group antigens: a modified calculation that corrects for transfusion exposures.
Gary Stack, Christopher A Tormey
Br J Haematol. 10, 2016.175(1):154-60 Print-Electronic
Source:PubMed
PMID: 27340943 doi:10.1111/bjh.14175
The changes necessary in the assessment of immunogenicity for the development of Biosimilars.
Johann Poetzl
Bioanalysis. Mar, 2025.17(5):355-358 Print-Electronic
Source:PubMed
PMID: 39901692 doi:10.1080/17576180.2025.2461373
IQ Survey Results on Current Industry Practices-Part 1: Immunogenicity Risk Assessment.
Christine Grimaldi, Susan Richards, Daniel Baltrukonis, Shelley Sims Belouski, Kelly Coble, Sanjay L Dholakiya, Joanna Grudzinska-Goebel, Gerry Kolaitis, Jocelyn H Leu, Linlin Luo, Stephen Lowe, Tao Niu, Henrik Toft-Hansen, Jianning Yang, Benjamin Wu
Clin Pharmacol Ther. Jan 28, 2025.: Print-Electronic
Source:PubMed
PMID: 39876095 doi:10.1002/cpt.3568
The AAPS Journal Theme Issue: Compendium of Immunogenicity Risk Assessments: an Industry Guidance Built on Experience and Published Work.
Johanna R Mora, Susan M Richards
AAPS J. 04 20, 2023.25(3):43 Electronic
Source:PubMed
PMID: 37081214 doi:10.1208/s12248-023-00796-4
2012 AAPS National Biotech Conference Open Forum: a perspective on the current state of immunogenicity prediction and risk management.
Manoj Rajadhyaksha, Meena Subramanyam, Bonnie Rup
AAPS J. Oct, 2013.15(4):1155-9 Print-Electronic
Source:PubMed
PMID: 23990501 doi:10.1208/s12248-013-9520-4
Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?
Jo Lambert, Alexander Nast, Frank O Nestle, Jörg C Prinz
J Dermatolog Treat. 2015.26(6):520-7 Print-Electronic
Source:PubMed
PMID: 26108443 doi:10.3109/09546634.2015.1034076
0